SPE2DP25F2792↗

Teva Pharmaceuticals USA, Inc. received this contract from Dla Troop Support, Defense Logistics Agency: $1.16M obligated so far for drugs and biologicals. Its period of performance ended 2025-02-04.

Key facts · data as of Oct 23, 2026

Recipient
Teva Pharmaceuticals USA, Inc.
Awarding agency
Defense Logistics Agency (Department of Defense)
Contracting office
Dla Troop Support (SPE2DP)
Obligated to date
$1.16M
Potential value
$1.16M
Ends
2025-02-04

Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.

Cite this page: SpendQuery, Award SPE2DP25F2792, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_SPE2DP25F2792_9700_SPE2DP20D0002_9700

8511148052!ADENOVIRUS TYPE 4 A

Delivery Order · Defense Logistics Agency · to Teva Pharmaceuticals USA, Inc. (UEI NEN9A34LRHJ5) · data as of 2026-10-23

Obligated to date$1.16M1 action
Current value$1.16Mwith options exercised
Period2025-01-28 → 2025-02-04current end date

What it is

Product or service
Drugs and Biologicals (PSC 6505)
Industry
Pharmaceutical Preparation Manufacturing (NAICS 325412)
Contracting office
Dla Troop Support (SPE2DP)
Competition
Not competed
Pricing
Firm fixed price
How it was bought
Single-award IDIQ · under SPE2DP20D0002
Where the work is
Morris, NJ · district NJ-11

Obligations by fiscal year

FY2025$1.16M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

1 action since 2025-01-28. Each is a modification or amendment with the money it added or took back.

DateModificationKindAmountWhat the agency wrote
2025-01-280$1.16M8511148052!ADENOVIRUS TYPE 4 A

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗